76693-04-4

Basic information

• Product Name: 4,4-diMethyl-1,2,3,4-tetrahydroquinolin-2-one
• Synonyms: 4,4-DiMethyl-1,3-dihydroquinolin-2-one;4,4-DiMethyl-3,4-dihydro-1H-quinolin-2-one;2(1H)-Quinolinone, 3,4-dihydro-4,4-dimethyl-;4,4-diMethyl-1,2,3,4-tetrahydroquinolin-2-one;3,4-dihydro-4,4-dimethylquinolin-2(1H)-one
• CAS NO: 76693-04-4
• Molecular Formula: C₁₁H₁₃NO
• Molecular Weight: 175.22702
• Mol File: 76693-04-4.mol
• Article Data: 27

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4,4-diMethyl-1,2,3,4-tetrahydroquinolin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4-diMethyl-1,2,3,4-tetrahydroquinolin-2-one(76693-04-4)
• EPA Substance Registry System: 4,4-diMethyl-1,2,3,4-tetrahydroquinolin-2-one(76693-04-4)

Safety Data

• Hazardous Substances Data: 76693-04-4(Hazardous Substances Data)

Usage

General Description

4,4-diMethyl-1,2,3,4-tetrahydroquinolin-2-one is a chemical compound with the molecular formula C12H15NO. It is a cyclic amide derivative, specifically a tetrahydroquinolinone, and it contains a quinoline ring system. 4,4-diMethyl-1,2,3,4-tetrahydroquinolin-2-one has applications in organic synthesis, pharmaceuticals, and agrochemicals. It is known for its potential biological activity and has been studied for its potential use as an anti-inflammatory and analgesic agent. Additionally, it has been investigated for its potential use as a building block in the synthesis of various organic compounds. Overall, 4,4-diMethyl-1,2,3,4-tetrahydroquinolin-2-one is a versatile chemical compound with various potential applications in the field of organic chemistry and pharmacology.

Upstream product

• 13209-80-8 N-phenyl-3-methyl-2-butenamide 
• 62-53-3 aniline 
• 3350-78-5 3,3-Dimethylacryloyl chloride 
• 71-43-2 benzene 
• 26465-81-6 3,3-dimethylindan-1-one 
• 1010-48-6 3-methyl-3-phenylbutanoic acid 
• 359764-25-3 (COD)Pd(CH₂CMe₂C₆H₄) 
• 203311-15-3 (COD)Pd(CH₂CMe₂C₆H₅)Cl 
• 7073-99-6 2-tert-butylbromobenzene 
• 198206-03-0 2-(trimethylsilyl)phenyl trifluoromethanesulfonate 
• 541-47-9 3-Methylbutenoic acid 

Downstream Products

• 20364-31-2 4,4-dimethyl-1,2,3,4-tetrahydroquinoline 
• 873056-11-2 4,4-dimethyl-7-nitro-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 873056-12-3 tert-butyl 7-amino-3,4-dihydro-4,4-dimethylquinoline-1(2H)-carboxylate 
• 870072-60-9 4,4-dimethyl-1-(2-nitro-phenyl)-1,2,3,4-tetrahydroquinoline 
• 870072-61-0 2-(4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)aniline 
• 117241-97-1 4,4-dimethyl-6-nitro-3,4-dihydro-1H-quinolin-2-one 
• 1070973-20-4 4-[5-chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-(4,4-dimethyl-3,4-dihydro-2H-quinoline-1-sulfonyl)-phenoxy]-butyric acid 
• 1070973-14-6 5-[2-chloro-5-(4,4-dimethyl-3,4-dihydro-2H-quinoline-1-sulfonyl)-4-(4-hydroxy-butoxy)-phenyl]-2-trifluoromethyl-isonicotinonitrile 
• 1070973-17-9 4-[5-chloro-2-(4,4-dimethyl-3,4-dihydro-2H-quinoline-1-sulfonyl)-4-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl)-phenoxy]-butan-1-ol 
• 1070973-34-0 2-[4-bromo-5-chloro-2-(4,4-dimethyl-3,4-dihydro-2H-quinoline-1-sulfonyl)-phenyl]-malonic acid dimethyl ester 
• 1070973-35-1 2-[4-bromo-5-chloro-2-(4,4-dimethyl-3,4-dihydro-2H-quinoline-1-sulfonyl)-phenyl]-acetic acid methyl ester 
• 1070973-15-7 1-(5-bromo-4-chloro-2-fluoro-benzenesulfonyl)-4,4-dimethyl-1,2,3,4-tetrahydro-quinoline 
• 1392286-48-4 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide 
• 1392286-47-3 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, lI-P, or III. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH).

Room Temperature Benzofused Lactam Synthesis Enabled by Cobalt(III)-Catalyzed C(sp2)?H Amidation

Benzofused lactams, especially indolin-2-one and dihydroquinolin-2-one are popular structural motives in durgs and natural products. Herein, we developed a room temperature and robust synthesis of benzofused lactams through cobalt(III)-catalyzed C(sp

Schmidt reaction on substituted 1-indanones / N-alkylation: Synthesis of benzofused six-membered ring lactams and their evaluation as antimicrobial agents

Background: The presence of bicyclic lactams is reflected in various pharmaceuticals, natural products, agrochemicals and active components of various dyes. Nowadays, to see the increasing rate of antimicrobial resistance and high incidence of microbial infections, there is a strong need to develop novel antimicrobial agents. In this study, we synthesized some benzofused six membered ring lactams and their alkyl derivatives as a trial to obtain valuable precursors for the discovery of future an-timicrobial drugs. Methods: The substituted lactams 3,4-dihydro-2(1H)-quinolinones 3a-c and 3,4-dihydro-1(2H)-isoquinolinones 4a-c were synthesized by Schmidt reaction on indanones 2a-c which were obtained by Friedel-Crafts reaction on β-substituted α,β-unsaturated carboxylic acids 1a-c. Lactams 6 and 7 were obtained by N-alkylation on benzofused lactams 3a-c and 4a-c in good to excellent yields. Structures of all products were well characterized by the rigorous analysis of their IR,1H NMR,13C NMR, MS and elemental analysis. The in vitro antimicrobial activities of all the synthesized compounds 6 and 7 were determined against Gram-positive, Gram-negative bacteria and the fungal species Candida albi-cans using broth macrodilution method. Results: The Schmidt reaction of 3-methylindanone, 3-phenylindanone and 3,3-dimethylindanone using methane sulphonic acid was found to behave differently with respect to isolated yield as well as isomeric ratio of both lactams. Bacterial growth inhibition was observed with bicyclic lactam derivatives although their MIC values were higher than ampicillin. The significant inhibitory effects were shown by majority of compounds with MIC values 125-250 μg/ml. Antifungal activity of bicyclic lactam derivatives was observed against C. albicans. However, MICs values of all tested compounds were higher compared to standard antifungal agent miconazole. Conclusion: The four Schmidt experimental conditions were tried with the aim of achieving both 6-membered ring lactams in equal ratio and NaN3/MeSO3H was identified to fulfill our purpose. As evident by structure-activity relationship, the tested compounds have not resulted in superior antibacterial or anti-fungal compounds compared to standard antimicrobials. Hence, there is still a need to carry out further modifications in bicyclic lactams structure in order to more efficacious antimicrobial lead molecules.